Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer

NCT03738228 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03738228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03738228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
January 7, 2019
Completion date
September 12, 2025
Enrollment
40 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

cervical adenocarcinoma, cervical adenosquamous carcinoma, cervical squamous cell carcinoma, stage ib2 cervical cancer ajcc v8, stage ii cervical cancer ajcc v8, stage iia cervical cancer ajcc v8, stage iia1 cervical cancer ajcc v8, stage iia2 cervical cancer ajcc v8, stage iib cervical cancer ajcc v8, stage iiib cervical cancer ajcc v8, stage iva cervical cancer ajcc v8